Evidence map›Paper›PMID 39519450›Full record

SynthesisNutrients2024

Magnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population: A Systematic Review and Subgroup Meta-Analysis for Optimal Dosage and Treatment Length.

Benjamin J Behers, Brett M Behers, Christoph A Stephenson-Moe, Ian A Vargas, Zhuo Meng, Anthony J Thompson, Julian Melchor, Caroline N Wojtas, Manuel A Rosario, Joel F Baker and 3 more

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Metabolism open · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Benjamin J BehersDepartment of Clinical Sciences, Florida State University College of Medicine, Tallahassee, FL 32304, USA.ORCID 0000-0002-2951-7244
Brett M BehersDepartment of Clinical Research, University of South Florida College of Medicine, Tampa, FL 33602, USA.
Christoph A Stephenson-MoeDepartment of Clinical Sciences, Florida State University College of Medicine, Tallahassee, FL 32304, USA.
Ian A VargasFlorida State University Internal Medicine Residency at Sarasota Memorial Hospital, Sarasota, FL 34239, USA.
Zhuo MengDepartment of Statistics, Florida State University, Tallahassee, FL 32306, USA.
Anthony J ThompsonDepartment of Clinical Sciences, Florida State University College of Medicine, Tallahassee, FL 32304, USA.
Julian MelchorDepartment of Clinical Sciences, Florida State University College of Medicine, Tallahassee, FL 32304, USA.
Caroline N WojtasFlorida State University Internal Medicine Residency at Sarasota Memorial Hospital, Sarasota, FL 34239, USA.
Manuel A RosarioFlorida State University Internal Medicine Residency at Sarasota Memorial Hospital, Sarasota, FL 34239, USA.
Joel F BakerFlorida State University Internal Medicine Residency at Sarasota Memorial Hospital, Sarasota, FL 34239, USA.
Alexander C DeeversDepartment of Clinical Research, University of Florida, Gainesville, FL 32603, USA.
Roxann W MouratidisDepartment of Clinical Sciences, Florida State University College of Medicine, Tallahassee, FL 32304, USA.
Michael J SweeneyDepartment of Clinical Sciences, Florida State University College of Medicine, Tallahassee, FL 32304, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesStudies have shown that consistent reductions of 2 mm Hg in systolic blood pressure (SBP) for the general normotensive population can result in significant decreases in mortality from heart disease and stroke. The purpose of this meta-analysis was to determine the optimal dose and duration of treatment for magnesium and potassium supplementation, having previously discovered that both reduce SBP by -2.79 and -2.10 mm Hg, respectively.

methodsPlacebo-controlled, randomized clinical trials examining the effects of magnesium and potassium supplementation on SBP were identified. Pairwise meta-analyses with subgroups for dosage and treatment duration were run.

resultsMagnesium at dosages of ≤360 mg/day and durations greater than 3 months reduced SBP by -3.03 and -4.31 mm Hg, respectively. Potassium at dosages of ≤60 mmol/day and durations greater than 1 month reduced SBP by -2.34 and -2.80 mm Hg, respectively.

conclusionsBoth supplements demonstrated greater reductions in SBP for the general population at lower dosages and longer treatment durations. Future studies are needed to validate these findings and provide tailored recommendations. These studies could investigate varying dosages over long-term follow-up to provide robust data on optimal dosages and treatment durations, as our findings were limited due to reliance on previously published trials.

Indexed as

Blood PressureDietary SupplementsMagnesiumDose-Response Relationship, DrugHumansHypertensionPotassiumRandomized Controlled Trials as TopicMagnesiumPotassiumcardiovascular diseaseheart diseasemagnesiumnutraceuticalspotassiumstroke

Identifiers

PMID39519450
PMCPMC11547496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.